Current as of 06/06/2023

Adj/Professor Alison Todd (PhD, FTSE)

Alison Todd is the co-founder and Chief Scientific Officer and of SpeeDx Pty Ltd; an Australian Molecular Diagnostics company with headquarters in Sydney and subsidiaries in the UK and USA. SpeeDx has an advanced manufacturing facility that produces a range of regulatory-approved, human IVD tests which are sold globally into 17 countries.

Alison’s career has focused on developing and commercialising diagnostic tools for tailoring and monitoring therapy for patients with cancer or infectious diseases. She is a serial inventor with over 200 granted patents describing inventions which underpin SpeeDx’s product portfolio.

Prior to founding SpeeDx, Alison spent nearly 20 years within the pharmaceutical industry working at Johnson and Johnson Research Pty Limited, Sydney. She obtained a BSc (Hons 1) and a PhD through the University of Sydney and maintains an active involvement with the academic community through her appointment as an Adjunct Professor at the University of New South Wales (UNSW). Alison serves on numerous committees and advisory groups including the AusBiotech NSW Leadership Committee and UNSW BABS Industry Advisory Committee.

Alison has been the recipient of numerous prestigious awards including the Prime Minister's Prize for Innovation (2022); the Australian Company of the Year (2021); ATSE’s Clunies Ross Award for Innovation (2020) and the Johnson & Johnson Philip B. Hofmann Research Scientist Award (1997).

Dr Alison Todd's fundamental work on the basic molecular mechanisms in the cell has led her to create a whole new molecular 'lego' that is opening the door to personalised clinical diagnostics. Since founding SpeeDx Pty Ltd in 2009 (https://plexpcr.com), Alison has created a multidisciplinary, rapidly expanding, global company that provides employment, training and manufacturing facilities in Australia. National & export sales are growing rapidly. SDX has a strong pipeline of new products. First FDA approval of a SpeeDx product, expected in 2Q19, will provide another significant value inflection point for patients worldwide and for Australia.